HUP0202202A3 - Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof - Google Patents

Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof

Info

Publication number
HUP0202202A3
HUP0202202A3 HU0202202A HUP0202202A HUP0202202A3 HU P0202202 A3 HUP0202202 A3 HU P0202202A3 HU 0202202 A HU0202202 A HU 0202202A HU P0202202 A HUP0202202 A HU P0202202A HU P0202202 A3 HUP0202202 A3 HU P0202202A3
Authority
HU
Hungary
Prior art keywords
benzoxepino
analogues
receptor antagonists
chemokine receptor
pyridine derivatives
Prior art date
Application number
HU0202202A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Kk filed Critical Kyowa Hakko Kogyo Kk
Publication of HUP0202202A2 publication Critical patent/HUP0202202A2/hu
Publication of HUP0202202A3 publication Critical patent/HUP0202202A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/12—[b,e]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
HU0202202A 1999-07-28 2000-07-28 Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof HUP0202202A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/362,837 US6509346B2 (en) 1998-01-21 1999-07-28 Chemokine receptor antagonists and methods of use therefor

Publications (2)

Publication Number Publication Date
HUP0202202A2 HUP0202202A2 (hu) 2002-11-28
HUP0202202A3 true HUP0202202A3 (en) 2003-05-28

Family

ID=23427735

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202202A HUP0202202A3 (en) 1999-07-28 2000-07-28 Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof

Country Status (17)

Country Link
US (2) US6509346B2 (https=)
EP (1) EP1204665B1 (https=)
JP (1) JP4903333B2 (https=)
KR (1) KR20020016926A (https=)
CN (1) CN1471536A (https=)
AT (1) ATE420090T1 (https=)
AU (1) AU6391400A (https=)
BR (1) BR0013065A (https=)
CA (1) CA2391267A1 (https=)
DE (1) DE60041336D1 (https=)
EA (1) EA200200194A1 (https=)
ES (1) ES2321798T3 (https=)
HK (1) HK1044333A1 (https=)
HU (1) HUP0202202A3 (https=)
IL (1) IL147852A0 (https=)
MX (1) MXPA02000978A (https=)
WO (1) WO2001009138A2 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7271176B2 (en) * 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
MXPA04004826A (es) * 1998-09-04 2004-08-11 Millenium Pharmaceuticals Inc Antagonista del receptor de quimioquinas y metodos para su uso.
US6919313B2 (en) * 2001-03-30 2005-07-19 President & Fellows Of Harvard College Protein waving a PDZ and a RGS domain
US7541365B2 (en) * 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
NZ596484A (en) * 2001-11-21 2013-05-31 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
US20060019977A1 (en) * 2002-10-18 2006-01-26 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient
TWI291467B (en) * 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
CA2520660C (en) * 2003-03-28 2013-08-20 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
CN100526301C (zh) * 2003-12-26 2009-08-12 卫材R&D管理有限公司 1,2-二(环式基)取代苯化合物
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
US20060276465A1 (en) * 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
US7410971B2 (en) * 2003-12-26 2008-08-12 Eisai R&D Management Co., Ltd. 1,2-di(cyclic)substituted benzene compounds
DE102004004719A1 (de) * 2004-01-29 2005-08-18 Basf Ag Verfahren zur Herstellung von enantiomerenreinen Aminoalkoholen
EP2444071A1 (en) * 2004-09-27 2012-04-25 Sigmoid Pharma Limited Minicapsule formulations
ATE553761T1 (de) 2004-12-17 2012-05-15 Millennium Pharm Inc Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür
EP1832580A4 (en) 2004-12-20 2009-03-11 Eisai R&D Man Co Ltd 1-CYCLOPROPYLMETHYL-4-Ý2- (3,3,5,5) -TETRAMETHYLCYCLOHEXYL) PHENYL PIPERAZINE CRYSTAL AND SALT
MY144974A (en) * 2005-06-14 2011-11-30 Eisai R&D Man Co Ltd 1,2-di(cyclic) substituted benzene derivatives
EP2079456B1 (en) 2007-04-04 2012-12-05 Sigmoid Pharma Limited Pharmaceutical cyclosporin compositions
EP2586428B1 (en) * 2007-04-26 2023-11-08 Sublimity Therapeutics Limited Manufacture of multiple minicapsules
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
US20090286823A1 (en) * 2007-12-17 2009-11-19 Millennium Pharmaceuticals Inc. CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
ES2649112T3 (es) 2009-05-18 2018-01-10 Sigmoid Pharma Limited Composición que comprende gotas de aceite
CN107582526A (zh) 2009-08-12 2018-01-16 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
US8859777B2 (en) 2010-04-30 2014-10-14 Kinentia Biosciences Llc 4-fluoro-4-arylpiperdin-1-yl derivatives as mu opioid function moderators
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
KR101102335B1 (ko) * 2011-09-06 2012-01-03 (주)칠칠공사 수영 연습용 가변형 풀
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
EP3881829A1 (en) 2014-11-07 2021-09-22 Sublimity Therapeutics Limited Compositions comprising cyclosporin
CN115389659B (zh) * 2022-08-23 2024-07-16 浙江中医药大学 一种细胞膜键合磁性碳球复合材料及其制备方法和应用

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE80449C (https=)
GB1003292A (en) 1960-12-08 1965-09-02 Sandoz Ag Improvements in or relating to 4-azathiaxanthene derivatives
NL132137C (https=) * 1963-04-24
BE664609A (https=) 1964-06-01
CH421138A (de) 1965-11-04 1966-09-30 Wander Ag Dr A Verfahren zur Herstellung von Thioxanthenderivaten
US3409621A (en) 1966-04-01 1968-11-05 Schering Corp Piperazino-aza-dibenzo-[a, d]-cycloheptenes
US3625974A (en) 1967-04-28 1971-12-07 Fujisawa Pharmaceutical Co Dibenzothiazepine derivatives
NL6905642A (https=) 1968-04-12 1969-10-14
GB1330966A (en) 1970-12-22 1973-09-19 Yoshitomi Pharmaceutical N-substituted piperidine compounds methods for their production and pharmaceutical compositions containing them
US3770729A (en) 1970-12-22 1973-11-06 Yoshitomi Pharmaceutical N substituted piperidine compounds
CA1010870A (en) 1972-12-08 1977-05-24 Niels Lassen Thiaxanthene derivative and method
US4250176A (en) 1976-12-21 1981-02-10 Janssen Pharmaceutica N.V. Piperazine derivatives
US4335122A (en) 1981-03-18 1982-06-15 Hoechst-Roussel Pharmaceuticals Inc. Dihydro-dibenzoxepines-thiepines and -morphanthridones, compositions and use
DE3326641A1 (de) 1982-07-27 1984-02-02 Basf Ag, 6700 Ludwigshafen 5,6-dihydro-11-h-morphantridin-6-one, ihre herstellung und diese enthaltende arzneimittel
CA1237428A (en) 1983-06-24 1988-05-31 Hiroshi Tanaka ¬1| benzepino¬3,4-b|pyridine derivative
DE3402060A1 (de) 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
JPH0665664B2 (ja) 1985-01-18 1994-08-24 大塚製薬株式会社 モルフアントリジン誘導体
SE8500273D0 (sv) 1985-01-22 1985-01-22 Leo Ab Nya tricykliska foreningar, kompositioner innehallande sadana foreningar, framstellningsforfaranden och behandlingsmetoder
JPS6310784A (ja) 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
WO1988000049A1 (fr) * 1986-06-26 1988-01-14 Kyowa Hakko Kogyo Co., Ltd. Agent antiarythmique
US5089496A (en) 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
IT8721978A0 (it) 1987-09-21 1987-09-21 Angeli Inst Spa Nuovi derivati ammidinici triciclici.
US4882351A (en) 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
AU612437B2 (en) 1987-12-14 1991-07-11 Kyowa Hakko Kogyo Co. Ltd. Tricyclic compounds
EP0411048A1 (en) 1988-04-28 1991-02-06 Schering Corporation Novel benzopyrido piperidine, piperidylidene and piperazine compounds, compositions, methods of manufacture and methods of use
CA1338625C (en) 1988-06-09 1996-10-01 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
US5242931A (en) 1988-06-09 1993-09-07 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds as TXA2 antagonists
DE3838912A1 (de) 1988-11-17 1990-05-23 Thomae Gmbh Dr K Mittel zur behandlung von akuten und chronischen obstruktiven atemwegserkrankungen
JPH0694464B2 (ja) 1991-01-23 1994-11-24 協和醗酵工業株式会社 三環式化合物およびその中間体
EP0511477B1 (en) 1991-03-11 1996-07-10 Kyowa Hakko Kogyo Co., Ltd. Indole derivatives
WO1992016226A1 (en) 1991-03-19 1992-10-01 Smithkline Beecham Corporation Il-1 inhibitors
WO1992020681A1 (en) 1991-05-23 1992-11-26 Schering Corporation Novel benzopyrido piperidylidene compounds, compositions, methods of manufacture and methods of use
WO1993002081A1 (en) 1991-07-23 1993-02-04 Schering Corporation Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use
US5378701A (en) 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US5679703A (en) 1992-09-16 1997-10-21 Kyowa Hakko Kogyo, Co., Ltd. Tricyclic compounds having ACAT inhibiting activity
US5538986A (en) 1993-12-06 1996-07-23 Schering Corporation Tricyclic derivatives, compositions and methods of use
MY113463A (en) 1994-01-04 2002-03-30 Novo Nordisk As Novel heterocyclic compounds
US5801175A (en) 1995-04-07 1998-09-01 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
WO1996031470A1 (en) 1995-04-07 1996-10-10 Novo Nordisk A/S Novel heterocyclic compounds
UA54385C2 (uk) 1995-04-07 2003-03-17 Ново Нордіск А/С N-заміщені азагетероциклічні карбонові кислоти та їх ефіри, спосіб їх одержання, фармацевтична композиція та спосіб лікування
AU5270796A (en) 1995-04-07 1996-10-23 Novo Nordisk A/S N-substituted azaheterocyclic carboxylic acids and esters th ereof
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
JPH0940662A (ja) 1995-05-24 1997-02-10 Kyowa Hakko Kogyo Co Ltd 三環式化合物
US6150355A (en) 1995-09-13 2000-11-21 Kyowa Hakko Kogyo Co., Ltd. Phenylpiperidine derivative
AU1208397A (en) 1995-12-28 1997-07-28 Takeda Chemical Industries Ltd. Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists
DE69709647T2 (de) 1996-05-20 2002-11-07 Dupont Pharmaceuticals Research Laboratories, Inc. Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren
JP2000516210A (ja) 1996-07-12 2000-12-05 ロイコサイト，インコーポレーテッド ケモカインレセプターアンタゴニストとその使用方法
US6323206B1 (en) 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2261633A1 (en) 1996-07-29 1998-02-05 Banyu Pharmaceutical Co., Ltd. Chemokine receptor antagonists
AU4801197A (en) 1996-09-13 1998-04-02 Schering Corporation Tricyclic antitumor compounds being farnesyl protein transferase inhibit ors
CN1237176A (zh) 1996-09-13 1999-12-01 先灵公司 用作fpt抑制剂的三环化合物
CA2264666A1 (en) 1996-09-13 1998-03-19 Schering Corporation Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase
CN1104427C (zh) 1996-09-13 2003-04-02 先灵公司 法呢基蛋白转移酶的三环抑制剂
CZ84199A3 (cs) 1996-09-13 1999-11-17 Schering Corporation Nové, tricyklické piperidinylové sloučeniny použitelné jako inhibitory farnesylprotein transferasy
NZ334437A (en) 1996-09-13 2000-09-29 Schering Corp Substituted benzocycloheptapyridine derivatives useful for inhibition of farnesyl protein transferase
IL128949A0 (en) 1996-09-13 2000-02-17 Schering Corp Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
CA2267500A1 (en) 1996-10-04 1998-04-16 Novo Nordisk A/S N-substituted azaheterocyclic compounds
AU5604998A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
WO1998025605A1 (en) 1996-12-13 1998-06-18 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
AU5522498A (en) 1996-12-13 1998-07-03 Merck & Co., Inc. Substituted aryl piperazines as modulators of chemokine receptor activity
AU5812498A (en) 1996-12-20 1998-07-17 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
AU6517398A (en) 1997-03-27 1998-10-22 Kyowa Hakko Kogyo Co. Ltd. Therapeutic agent for autoimmune diseases
ES2273413T3 (es) 1997-04-15 2007-05-01 Kyowa Hakko Kogyo Co., Ltd. Compuestos triciclicos.
US5877177A (en) 1997-06-17 1999-03-02 Schering Corporation Carboxy piperidylacetamide tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US6040318A (en) 1997-06-25 2000-03-21 Novo Nordisk A/S Tricycle substituted with azaheterocyclic carboxylic acids
US6048856A (en) 1997-12-17 2000-04-11 Novo Nordisk A/S Heterocyclic compounds
BR9910144A (pt) 1998-01-21 2002-04-02 Millennium Pharm Inc Antagonistas de receptores de quimiocinas e seu uso
US6613905B1 (en) * 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6433165B1 (en) 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2343536A1 (en) 1998-09-04 2000-03-16 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
HUP0202202A2 (hu) 2002-11-28
JP4903333B2 (ja) 2012-03-28
EA200200194A1 (ru) 2002-08-29
ES2321798T3 (es) 2009-06-12
CA2391267A1 (en) 2001-02-08
ATE420090T1 (de) 2009-01-15
MXPA02000978A (es) 2002-08-12
BR0013065A (pt) 2002-07-30
WO2001009138A3 (en) 2001-09-13
DE60041336D1 (de) 2009-02-26
US20030045516A1 (en) 2003-03-06
EP1204665A2 (en) 2002-05-15
HK1044333A1 (zh) 2002-10-18
KR20020016926A (ko) 2002-03-06
AU6391400A (en) 2001-02-19
US6509346B2 (en) 2003-01-21
IL147852A0 (en) 2002-08-14
WO2001009138A2 (en) 2001-02-08
JP2003506377A (ja) 2003-02-18
CN1471536A (zh) 2004-01-28
US20020119973A1 (en) 2002-08-29
EP1204665B1 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
HUP0202202A3 (en) Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof
SI1035115T1 (en) 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
IL141506A0 (en) 4,4-biarylpiperidine derivatives with opioid receptor activity
GB9911053D0 (en) 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
AU6751301A (en) 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists
IL148419A0 (en) Benzodiazepine derivatives, the production and use thereof
PL347885A1 (en) Azepinoindole derivatives, the production and use thereof
IL144851A0 (en) 3-phenylpyridine derivatives and their use as nk-1 receptor antagonists
IL150022A0 (en) Imidazo [1,3,5] triazinones and the use thereof
AU4846597A (en) Vitronectin receptor antagonists, their preparation and their use
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
HRP20000002B1 (en) Azetidinylpropylpiperidine derivatives, intermediates and use as tachykinin antagonists
AU4846497A (en) Vitronectin receptor antagonists, their preparation and their use
HUP0203371A3 (en) Adenosine receptor antagonists and methods of making and using the same
IL135451A0 (en) 3-amino-3-arylpropan-1-ol derivatives, their preparation and use
IL145166A0 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor
PL351794A1 (en) 4-heterocyclysulfonamidyl-6-methoxy-5-(2-methoxy-phenoxy)-2-pyridyl-pyrimidine derivatives, their preparation and use as endothelin receptor antagonists
HUP0500079A3 (en) Chemokine receptor antagonists, their use and pharmaceutical compositions containing them
IL130251A0 (en) Heterocyclic carboxylic acid derivatives the production and use thereof as endothelin receptor antagonists
AU5861900A (en) Receptor agonists and antagonists
IL133104A0 (en) New - beta-amino and beta-azidocarboxylic acid derivatives the production thereof and the use thereof as endothelin receptor antagonists
AU4980999A (en) A3 adenosine receptor antagonists
AU2574801A (en) Selective iGLUR5 receptor antagonists
IL142362A0 (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists
AU1025601A (en) Tetrahydrobenzindolone derivatives, their preparation and their use as 5-ht7 receptor antagonists